Design, synthesis, and antiviral evaluations of 1-(substituted benzyl)- 2-substituted-5,6-dichlorobenzimidazoles as nonnucleoside analogues of 2,5,6- trichloro-1-(β-D-ribofuranosyl)benzimidazole

Journal of Medicinal Chemistry

Volumn 41, Issue 8, 1998, Pages 1252-1262

  Porcari, Anthony R ^c   Devivar, Rodrigo V ^a   Kucera, Louis S ^b   Drach, John C ^c   Townsend, Leroy B ^c  

^a FlowGenix Corporation   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; STRUCTURE ACTIVITY RELATION; VIRUS CULTURE;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL DIVISION; CELL SURVIVAL; CYTOMEGALOVIRUS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FIBROBLASTS; HERPESVIRUS 1, HUMAN; HIV-1; HIV-2; HUMANS; KB CELLS; MICROBIAL SENSITIVITY TESTS; PLAQUE ASSAY; RIBONUCLEOSIDES; RNA-DIRECTED DNA POLYMERASE; SKIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032499283     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970559i     Document Type: Article

References (44)

1. McKenzie, R.; Travis, W. D.; Dolan, S. A.; Pittaluga, S.; Feuerstein, I. M.; Shelhamer, J.; Yarchoan, R.; Masur, H. The Causes of Death in Patients with Human Immunodeficiency Virus Infection: A Clinical and Pathological Study with Emphasis on the Role of Pulmonary Diseases. Medicine 1991, 70, 326-343.
2. Alford, C. A.; Stagno, S.; Pass, R. F.; Britt, W. J. Congenital and Perinatal Cytomegalovirus Infections. Rev. Infect. Dis. 1990, 12, S745-S753.
3. Rubin, R. H. Impact of Cytomegalovirus Infection on Organ Transplant Recipients. Rev. Infect. Dis. 1990, 12, S754-S766.
4. Wingard, J. R.; Piantadosi, S.; Burns, W. H.; Zahurak, M. L.; Santos, G. W.; Saral, R. Cytomegalovirus Infections in Bone Marrow Transplant Recipients Given Intensive Cytoreductive Therapy. Rev. Infect. Dis. 1990, 12, S793-S804.
5. (a)Faulds, D.; Heel, R. C. Ganciclovir: A Review of Its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy in Cytomegalovirus Infections. Drugs 1990, 39, 597-638.
6. (b) Crumpacker, C. S. Ganciclovir. Drug Ther. 1996, 335, 721-729.
7. Astra Pharmaceutical Products, Inc., Westborough, MA. FOSCAVIR (Foscarnet sodium) Injection, package insert.
8. Jacobsen, M. A.; O'Donnel, J. J.; Mills, J. Foscarnet Treatment of Cytomegalovirus Retinitis In Patients with Acquired Immunodeficiency Syndrome. Antimicrob. Agents Chemother. 1989, 33, 736-741.
9. (a) Hitchcock, M. J. M.; Jaffe, H. S.; Martin, J. C.; Stagg, R. J. Cidofovir, A New Agent with Potent Anti-Herpesvirus Activity. Antiviral Chem. Chemother. 1996, 7, 115-127.
10. (b) Kirsch, L. S.; Arevalo, J. F.; De Clercq, E.; Chavez, de la Paz. E.; Munguia, D.; Garcia, R.; Freeman, W. R. Phase I/II Study of Intravitreal Cidofovir For the Treatment of Cytomegalovirus Retinitis in Patients with the Acquired Immunodeficiency Syndrome. Am. J. Ophthalmol. 1994, 7, 1-13.
11. Field, A. K.; Biron, K. K. "The End of Innocence" Revisited: Resistance of Herpesviruses to Antiviral Drugs. Clin. Microbiol. Rev. 1995, 39, 882-886.
12. Tamm, I.; Folkers, K.; Shunk, C. H.; Horsfall, F. L. Inhibition of Influenza Virus Multiplication by N-Glycosides of Benzimidazoles. J. Exp. Med. 1954, 99, 227-250.
13. Tamm, I.; Sehgal, P. B. Halobenzimidazole Ribosides and RNA Synthesis of Cells and Viruses. Adv. Virus Res. 1978, 22, 187-258.
14. (a) Tamm, I.; Overman, J. R. Relationship Between Structure of Benzimidazole Derivatives and Inhibitory Activity on Vaccinia Virus Multiplication. Virology 1957, 3, 185-196.
15. (b) Pothier, P.; Dru, A.; Beaud, G. The Inhibition of Vaccinia Virus Replication By 5,6-Dichloro-1-β-D-Ribofuranosylbenzimidazole (DRB): An effect at the assembly stage. J. Gen. Virol. 1981, 55, 87-94.
16. (a) Tamm, I. Ribonucleic Acid Synthesis and Influenza Virus Multiplication. Science 1957, 126, 1235-1236.
17. (b) Tamm, I.; Nemes, M. M.; Osterhout, S. On the Role of Ribonucleic Acid in Animal Virus Synthesis. I. Studies with 5,6-Dichloro-1-β-D-Ribofuranosylbenzimidazole. J. Exp. Med. 1960, 111, 339-349.
18. Sehgal, P. B.; Fraser, N. W.; Darnell J. E. Early Ad-2 Transcription Units: Only Promoter-Proximal RNA Continues to be Made in the Presence of DRB. Virology 1979, 94, 185-191.
19. Fraser, N. W.; Sehgal, P. B.; Darnell J. E. Multiple Discrete Sites For Premature RNA.-Chain Termination Late in Adenovirus-2 Infection: Enhancement By 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 2571-2575.
20. (a) Harlow, P.; Molloy, G. Effect of 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole on Ribonucleotide Metabolism and Accumulation of Mitochondrial RNA and Low-Molecular-Weight Cytoplasmic RNA in Hela Cells. Arch. Biochem. Biophys. 1980, 203, 764-773.
21. (b) Tamm, I.; Kikuchi, J. E.; Salditt-Georgieff, M. Short Capped hnRNA Precursor Chains in Hela Cells: Continued Synthesis in the Presence of 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole. Biochemistry 1980, 19, 2743-2748.
22. Chodosh, L. A.; Fire, A.; Samuels, M.; Sharp, P. A. 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole Inhibits Transcription Elongation By RNA Polymerase II in vitro. J. Biol. Chem. 1989, 264, 2250-2257.
23. Bucknall, R. A. The Effects of Substituted Benzimidazoles on the Growth of Viruses and the Nucleic Acid Metabolism of Host Cells. J. Gen. Virol. 1967, 1, 89-99.
24. Townsend, L. B.; Revankar G. R. Benzimidazole Nucleosides, Nucleotides, and Related Derivatives. Chem. Rev. (Washington, D.C.) 1970, 70, 389-438.
25. Townsend, L. B.; Devivar, R. V.; Turk, S. R.; Nassiri, M. R.; Drach, J. C. Design, Synthesis and Antiviral Activity of Certain 2,5,6-Trihalo-1-(β-D-Rribofuranosyl)benzimidazoles. J. Med. Chem. 1995, 38, 4098-4105.
26. Drach J. C.; Townsend, L. B.; Nassiri, M. R.; Turk, S. R.; Coleman, L. A.; Devivar, R. V.; Genzlinger, G.; Kreske, E. D.; Renau, T. E.; Westerman, A. C.; Shipman, C. Jr.; Biron, K. K.; Dornsife, R.; Kern, E. R. Benzimidazole Ribonucleosides: A New Class of Antivirals with Potent and Selective Activity Against Human Cytomegalovirus. Fifth International Conference on Antiviral Research, Vancouver, B. C. Canada, March 8-13, 1992.
27. (a) Underwood, M. R.; Biron, K. K.; Hemphill, M. L.; Miller, T. J.; Stanat, S. C.; Dornsife, R. E.; Drach, J. C.; Townsend, L. B.; Edwards, C. A.; Harvey, R. J. High Molecular Weight HCMV DNA Does Not Properly Mature in the Presence of 2-Bromo-5,6-dichloro-1-β-D-ribofuranosylbenzimidazoIe (BDCRB). Herpesvirus Workshop, Pittsburgh, PA, July 1993.
28. (b) Underwood, M. R.; Stanat, S. C.; Drach, J. C.; Harvey R. J.; Biron, K. K. Inhibition of HCMV DNA Processing By a New Class of Anti-HCMV Compounds Is Mediated Through the UL89 Gene Product. Herpesvirus Workshop, Vancouver, B.C., August 1994.
29. Devivar, R. V.; Kawashima, E.; Revankar, G. R.; Breitenbach, J. M.; Drach, J. C.; Townsend, L. B. Benzimidazole Ribonucleosides: Design, Synthesis, and Antiviral Evaluation of Certain 2-Alkylthio-5,6-dichloro-1-β-D-ribofuranosyl)benzimidazoles. J. Med. Chem. 1994, 37, 2942-2949.
30. Saluja, S.; Zou, R.; Drach, J. C.; Townsend, L. B. Structure Activity Relationships Among 2-Substituted 5,6-Dichloro-, 4,6-Dichloro- and 4,5-Dichloro-1-[(2-hydroxyethoxy)methyl]- and 1-[(1,3-Dihydroxy-2-propoxy)methyl]benzimidazoles. J. Med. Chem. 1996, 39, 881-891.
31. Topliss J. G. Utilization of Operational Schemes For Analog Synthesis in Drug Design. J. Med. Chem. 1972, 15, 1006-11.
32. (a) Koszalka, G. W.; Chamberlain, S. D.; Harvey, R. J.; Frick, L. W.; Good, S. S.; Davis, M. L.; Smith, A.; Drach, J. C.; Townsend, L. B.; Biron, K. K. Benzimidazoles For the Treatment of Human Cytomegalovirus Infections. Ninth International Conf. Antiviral Res., Fukushima, Japan, May, 1996, abst. 85.
33. (b) Biron, K. K.; Davis, M. G.; Stanat, S. C.; Walton, L. M.; Smith, A.; Koszalka, G. W.; Drach, J. C.; Townsend, L. B.; Harvey, R. J. Antiviral Activity and Mechanism of Action of 1263w94, A Benzimidazole Riboside Inhibitor of Human Cytomegalovirus. 36th Interscience Conf. Antimicrob. Agents Chemother., New Orleans, LA, September 1996.
34. Bush, P. M.; Feng, K.; Townsend, L. B.; Drach, J. C. Selection and Characterization of HCMV with Increased Resistance to 2,5,6-Trihalogenated Benzimidazole Nucleosides. 21st Herpesvirus Workshop, DeKalb, IL, July 1996.
35. Adams, R.; Winnick, C. N. Quinone Imides. VIII. Synthesis and Reactions of o-Quinone Diimides. J. Am. Chem. Soc. 1951, 73, 5687-5691.
36. Turk, S. R; Shipman, C.; Nassiri, H.; Genzlinger, G.; Krawczyk, S. H.; Townsend, L. B.; Drach, J. C. Pyrrolo[2,3-d]pyrimidine Nucleosides As Inhibitors of Human Cytomegalovirus. Antimicrob. Agents Chemother. 1987, 31, 544-550.
37. Prichard, M. N.; Turk, S. R.; Coleman, L. A.; Engelhardt, S. L.; Shipman, C., Jr.; Drach, J. C. A Microtiter Virus Yield Reduction Assay For the Evaluation of Antiviral Compounds Against Human Cytomegalovirus and Herpes Simplex Virus. J. Virol. Methods 1990, 28, 101-106.
38. Larder, B. A.; Darby, G.; Richman, D. D. HIV With Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy. Science 1989, 243, 1731-1734.
39. Nunberg, J. H.; Schleif, W. A.; Boots, E. J.; O'Brien, J. A.; Quintero, J. C.; Hoffman, J. M.; Emini, A. M.; Goldman, M. E. Viral Resistance to Human Immunodeficiency Virus Type 1-Specific Pyridinone Reverse Transcriptase Inhibitors. J. Virol. 1991, 65, 4887-4892.
40. Kucera, L. S.; Iyer, N.; Leake, E.; Raben, A.; Modest, E. J.; Daniel, L. W.; and Piantadosi, C. Novel Membrane-Interactive Ether Lipid Analogs That Inhibit Infectious HIV-1 Production and Induce Defective Virus Formation. AIDS Res. Hum. Retroviruses 1990, 6, 491-501.
41. Kucera, L. S.; Iyer, N.; Puckett, S. H.; Buckheit, R. W.; Westbrook, L.; Toyer, B. R.; White, E. L. Germany-Decker, J. M.; Shannon, W. M.; Chen, R. C.-S.; Nassiri, M. R; Shipman, C.; Townsend, L. B.; Drach, J. C. Activity of Triciribine and Triciribine-5′-Monophosphate Against Human Immunodeficiency Virus Types 1 and 2. AIDS Res. Hum. Retroviruses 1993, 9, 307-314.
42. Prichard, M. N.; Shipman, C. A Three-Dimensional Model to Analyze Drug-Drug Interactions. Antiviral Res. 1990,14, 181-205.
43. White, E. L.; Buckheit, R. W.; Ross, L. J.; Germany, J. M.; Andries, K.; Pauwels, R.; Janssen P. A. J.; Shannon, W. M.; Chirigosm, M. A. A TIBO Derivative, R82913, is a Potent Inhibitor of HIV-1 Reverse Transcriptase with Heteropolymer Templates. Antiviral Res. 1991, 16, 257-266.
44. Prichard, M. N.; Prichard, L. E.; Baguley, W. A.; Nassiri, M. R.; Shipman, C. Three-Dimensional Analysis of the Synergistic Cytotoxicity of Ganciclovir and Zidovudine. Antimicrob. Agents Chemother. 1991, 35, 1060-1065.